1. Introduction {#sec1-jcm-08-00657}
===============

Gastric cancer (GC) is a global health-related burden and the fourth most common cause of cancer-related deaths worldwide \[[@B1-jcm-08-00657]\]. The sequential cascade of histopathology for development of intestinal-type gastric adenocarcinoma is from normal gastric epithelium to chronic gastritis, chronic atrophic gastritis (CAG), and intestinal metaplasia (IM), followed by dysplasia, and finally GC \[[@B2-jcm-08-00657]\]. Patients with premalignant lesions, such as CAG or dysplasia, have a considerable risk for developing GC, and early detection of these lesions is important for the screening of GC \[[@B3-jcm-08-00657],[@B4-jcm-08-00657]\].

For the population-based screening of GC, the endoscopic mass screening program has shown its efficacy in GC-prevalent countries such as Korea and Japan \[[@B5-jcm-08-00657]\]. The endoscopic screening program reduced GC-related mortality by 47% in a nested case-control study in Korea \[[@B6-jcm-08-00657]\]. However, it is not cost-effective in regions with low incidence of GC, and stepwise or individualized screening according to the risk factors of GC has been recommended \[[@B4-jcm-08-00657],[@B5-jcm-08-00657]\].

In addition to endoscopic diagnosis using visual inspection (with or without image-enhanced endoscopy) or histologic diagnosis using an updated Sydney system for CAG or IM, serum pepsinogen assay (sPGA), which reveals concentration of pepsinogen I (PG I) and ratio of PG I/PG II, has been proposed as a non-invasive test for predicting CAG or GC, reflecting gastric mucosal secretory status \[[@B4-jcm-08-00657],[@B7-jcm-08-00657]\].

Although various cut-off values have been suggested, the combination of PG I ≤70 ng/mL and PG I/PG II ratio ≤3 have been proposed for the prediction of CAG or GC \[[@B4-jcm-08-00657],[@B8-jcm-08-00657]\]. However, previous meta-analyses for diagnostic test accuracy (DTA) presented only pooled outcomes, which cannot determine the diagnostic validity of sPGA with a cut-off value of PG I ≤70 ng/mL and PG I/PG II ratio ≤3 \[[@B9-jcm-08-00657],[@B10-jcm-08-00657]\], although no threshold effect was detected \[[@B9-jcm-08-00657]\]. This can lead to an exaggerated summary of performance because pooled analysis adopted the best performance value in each study, irrespective of cut-off values. Moreover, several articles were omitted during article searching process, and inaccurate calculation of crude values of diagnostic performance, such as true positive (TP), false positive (FP), true negative (TN), and false negative (FN) values, was detected ([Table 1](#jcm-08-00657-t001){ref-type="table"}).

Another meta-analysis showed higher discriminative efficacy of combining sPGA with *Helicobacter pylori* antibody compared to sPGA or *H. pylori* antibody alone for the prediction of gastric cancer \[[@B11-jcm-08-00657]\]. However, this study presented only comparative efficacy and could not determine the diagnostic validity of each test. Two recently published meta-analyses of DTA showed combined test accuracy of sPGA with *H. pylori* antibody and gastrin-17 for the prediction of CAG (GastroPanel^®^) \[[@B12-jcm-08-00657],[@B13-jcm-08-00657]\]. However, this test is not widely available in Asian countries and also the diagnostic validity of sPGA alone was impossible to determine. Although two earlier meta-analyses presented pooled performance of sPGA with cut-off value of PG I ≤70 ng/mL and PG I/PG II ratio ≤3 \[[@B8-jcm-08-00657],[@B14-jcm-08-00657]\], crude values of diagnostic performance used in these studies are unknown. Moreover, diagnostic values with different cut-off standards were coded as those with PG I ≤70 ng/mL and PG I/PG II ratio ≤3, assuming an intrinsic cut-off effect ([Table 1](#jcm-08-00657-t001){ref-type="table"}).

Therefore, our study aims to provide evidence of sPGA with cut-off value of PG I ≤70 ng/mL and/or PG I/PG II ratio ≤3 for predicting CAG and gastric neoplasms.

2. Materials and Methods {#sec2-jcm-08-00657}
========================

This systematic review and meta-analysis fully adhered to the principles of the Preferred Reporting Items for Systematic reviews and Meta-Analyses for Protocols (PRISMA-P) \[[@B15-jcm-08-00657]\]. The protocol of this study was registered at PROSPERO on December 2018 (registration number, CRD42018116470) before the study was initiated. The approval of institutional review board was exempted as the study collected and synthesized data from published literatures \[[@B4-jcm-08-00657]\].

2.1. Literature Searching Strategy {#sec2dot1-jcm-08-00657}
----------------------------------

MEDLINE (through PubMed), the Cochrane library, and Embase were searched using common keywords associated with sPGA, CAG, and gastric neoplasms, from the time of inception of these databases to March 2019, by two independent evaluators (C.S.B., and J.J.L). Keywords from Medical Subject Heading and Emtree were selected for searching the electronic databases. Abstracts of all the identified studies were reviewed to exclude irrelevant publications. Full-text reviews were performed to determine whether the inclusion criteria were satisfied throughout all the studies. Bibliographies of relevant articles were rigorously reviewed to identify additional studies. Disagreements between the evaluators were resolved by discussion or consultation with a third evaluator (G.H.B.). The detailed searching strategy is described in [Table 2](#jcm-08-00657-t002){ref-type="table"} \[[@B4-jcm-08-00657]\].

2.2. Selection Criteria {#sec2dot2-jcm-08-00657}
-----------------------

We included studies that met the following criteria. Patients (1) who have CAG or gastric neoplasms (dysplasia or cancer); (2) intervention: sPGA with cut-off value of PG I ≤70 ng/mL and/or PG I/PG II ratio ≤3; (3) comparison: none; (4) outcome: diagnostic performance indices of sPGA for CAG or gastric neoplasms including sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR), negative likelihood ratio (NLR), accuracy, or diagnostic odds ratio (DOR), which enable an estimation of TP, FP, TN, and FN values; (5) study design: all types; (6) studies of human subjects; and (7) full-text publications written in English. Studies that met all of the inclusion criteria were sought and selected. The exclusion criteria were as follows: (1) narrative review; (2) letter, comment, editorial or reply to questions; (3) study protocol; (4) publication with incomplete data; and (5) systematic review/meta-analysis or consensus report. Studies meeting at least one of the exclusion criteria were excluded from this analysis.

2.3. Methodological Quality {#sec2dot3-jcm-08-00657}
---------------------------

The methodological quality of the included publications was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool, which contains four domains, including "patient selection", "index test", "reference standard", and "flow and timing" (flow of patients through the study and timing of the index tests and reference standard) \[[@B16-jcm-08-00657]\]. Each domain is assessed in terms of high-, low-, or unclear risk of bias, and the first three domains are also assessed in terms of high-, low-, or unclear concerns about applicability \[[@B16-jcm-08-00657]\]. Two of the evaluators (C.S.B. and J.J.L.) independently assessed the methodological quality of all the included studies, and any disagreements between the evaluators were resolved by discussion or consultation with a third evaluator (G.H.B.) \[[@B4-jcm-08-00657]\].

2.4. Data Extraction and Primary and Modifier-Based Analyses {#sec2dot4-jcm-08-00657}
------------------------------------------------------------

Two evaluators (C.S.B. and J.J.L.) independently used the same data fill-in form to collect the summary of primary outcomes (TP, FP, FN, and TN) and modifiers in each study. Disagreements between the two evaluators were resolved by discussion or consultation with a third author (G.H.B).

DTA was the primary outcome of this study. We calculated the values for TP (subjects with positive sPGA who have CAG or gastric neoplasms), FP (subjects with positive sPGA who do not have CAG or gastric neoplasms), FN (subjects with negative sPGA who have CAG or gastric neoplasms), and TN (subjects with negative sPGA who do not have CAG or gastric neoplasms) of sPGA for the diagnosis of CAG or gastric neoplasm. To calculate the values, we used 2 × 2 tables whenever possible, from the original articles that contain various diagnostic performance indices (sensitivity, specificity, PPV, NPV, PLR, NLR, accuracy, or DOR etc.). If only a part of data was presented, we calculated the values for TP, FP, FN, and TN using the following formulas: sensitivity = TP/(TP + FN); specificity = TN/(FP + TN); PPV = TP/(TP + FP); NPV = TN/(FN + TN); PLR = sensitivity/(1-specificity); NLR = (1-sensitivity)/specificity; accuracy = (TP + TN)/(TP + FP + FN + TN); DOR = (TP × TN)/(FP × FN); standard error = (ln(upper confidence interval (CI)) -- ln(lower CI))/3.92 = √(1/TP + 1/FP + 1/FN + 1/TN).

The following data were also extracted from each study, whenever possible: study design, distribution of age, gender or ethnicity of enrolled population, sample size, published year, measurement method of sPGA, and the proportion of smokers and *H. pylori*-infected individuals.

2.5. Statistical Analysis {#sec2dot5-jcm-08-00657}
-------------------------

Stata Statistical Software, version 15.1 (College Station, TX, USA) including relevant packages, such as metandi, midas, and mylabels, was used for this meta-analysis.

Narrative (descriptive) synthesis was planned and quantitative synthesis (bivariate random model \[[@B17-jcm-08-00657]\] and hierarchical summary receiver operating characteristic (HSROC) model \[[@B18-jcm-08-00657]\]) was used if the included studies were sufficiently homogenous. We calculated or extracted TP, FP, FN, and TN values from each study. A Forest plot of pooled sensitivity or specificity using a bivariate model and summary receiver operating characteristic (SROC) curve using a HSROC model were generated. Heterogeneity across the studies was determined by correlation coefficient between logit transformed sensitivity and specificity using bivariate model \[[@B17-jcm-08-00657]\] and asymmetry parameter, β (beta), where β = 0 corresponds to a symmetric receiver operating characteristic (ROC) curve in which the DOR does not vary along the curve by HSROC model. A positive correlation coefficient (greater than 0) and β with significant *p* value (*p* \< 0.05) indicate heterogeneity between studies \[[@B18-jcm-08-00657],[@B19-jcm-08-00657]\]. Visual examination of the SROC curve was also performed to find heterogeneity. We also performed meta-regression and subgroup analyses using the modifiers identified during the systematic review to confirm robustness of the main result and to identify the reason of heterogeneity. Publication bias was evaluated using Deeks' funnel plot asymmetry test.

3. Results {#sec3-jcm-08-00657}
==========

3.1. Identification of Relevant Studies {#sec3dot1-jcm-08-00657}
---------------------------------------

[Figure 1](#jcm-08-00657-f001){ref-type="fig"} presents a flow diagram showing the process to identify the relevant studies. For CAG diagnosis, a total of 855 articles were identified by searching four electronic databases and additional hand-searching. Among those articles, 174 were duplicate studies, and 552 additional studies were excluded during the initial screening by reviewing titles and abstracts. Full texts of the remaining 129 studies were then thoroughly reviewed. Among these studies, 115 articles were excluded from the final analysis due to the following reasons: narrative review article (*n =* 13), letter, comment, editorial or reply to questions (*n =* 1), study protocol (*n =* 1), incomplete data (*n =* 92), and systematic review/meta-analysis or consensus report (*n =* 8). The remaining 14 studies \[[@B20-jcm-08-00657],[@B21-jcm-08-00657],[@B22-jcm-08-00657],[@B23-jcm-08-00657],[@B24-jcm-08-00657],[@B25-jcm-08-00657],[@B26-jcm-08-00657],[@B27-jcm-08-00657],[@B28-jcm-08-00657],[@B29-jcm-08-00657],[@B30-jcm-08-00657],[@B31-jcm-08-00657],[@B32-jcm-08-00657],[@B33-jcm-08-00657]\] were included in the quantitative synthesis. Eight studies \[[@B20-jcm-08-00657],[@B23-jcm-08-00657],[@B24-jcm-08-00657],[@B27-jcm-08-00657],[@B29-jcm-08-00657],[@B30-jcm-08-00657],[@B31-jcm-08-00657],[@B32-jcm-08-00657]\] adopted the cut-off standard of PG I ≤70 ng/mL and PG I/PG II ratio ≤3, eight studies \[[@B21-jcm-08-00657],[@B22-jcm-08-00657],[@B25-jcm-08-00657],[@B26-jcm-08-00657],[@B27-jcm-08-00657],[@B28-jcm-08-00657],[@B30-jcm-08-00657],[@B33-jcm-08-00657]\] adopted the cut-off standard of PG I/PG II ratio ≤3, and only two studies \[[@B27-jcm-08-00657],[@B33-jcm-08-00657]\] adopted the cut-off standard of PG I ≤70 ng/mL.

For gastric neoplasm diagnosis, a total of 1408 articles were identified by searching four electronic databases. Among those articles, 538 were duplicate studies, and 685 additional studies were excluded during the initial screening by reviewing titles and abstracts. The full texts of the remaining 185 studies were then thoroughly reviewed. Among these studies, 142 articles were excluded from the final analysis, due to the following reasons: narrative review article (*n =* 30), letter, comment, editorial or reply to questions (*n =* 6), study protocol (*n =* 6), incomplete data (*n =* 88), and systematic review/meta-analysis or consensus report (*n =* 12). The remaining 43 studies \[[@B21-jcm-08-00657],[@B26-jcm-08-00657],[@B27-jcm-08-00657],[@B34-jcm-08-00657],[@B35-jcm-08-00657],[@B36-jcm-08-00657],[@B37-jcm-08-00657],[@B38-jcm-08-00657],[@B39-jcm-08-00657],[@B40-jcm-08-00657],[@B41-jcm-08-00657],[@B42-jcm-08-00657],[@B43-jcm-08-00657],[@B44-jcm-08-00657],[@B45-jcm-08-00657],[@B46-jcm-08-00657],[@B47-jcm-08-00657],[@B48-jcm-08-00657],[@B49-jcm-08-00657],[@B50-jcm-08-00657],[@B51-jcm-08-00657],[@B52-jcm-08-00657],[@B53-jcm-08-00657],[@B54-jcm-08-00657],[@B55-jcm-08-00657],[@B56-jcm-08-00657],[@B57-jcm-08-00657],[@B58-jcm-08-00657],[@B59-jcm-08-00657],[@B60-jcm-08-00657],[@B61-jcm-08-00657],[@B62-jcm-08-00657],[@B63-jcm-08-00657],[@B64-jcm-08-00657],[@B65-jcm-08-00657],[@B66-jcm-08-00657],[@B67-jcm-08-00657],[@B68-jcm-08-00657],[@B69-jcm-08-00657],[@B70-jcm-08-00657],[@B71-jcm-08-00657],[@B72-jcm-08-00657],[@B73-jcm-08-00657]\], including 38 studies \[[@B26-jcm-08-00657],[@B34-jcm-08-00657],[@B35-jcm-08-00657],[@B36-jcm-08-00657],[@B37-jcm-08-00657],[@B38-jcm-08-00657],[@B39-jcm-08-00657],[@B40-jcm-08-00657],[@B41-jcm-08-00657],[@B42-jcm-08-00657],[@B43-jcm-08-00657],[@B44-jcm-08-00657],[@B45-jcm-08-00657],[@B46-jcm-08-00657],[@B47-jcm-08-00657],[@B48-jcm-08-00657],[@B49-jcm-08-00657],[@B50-jcm-08-00657],[@B51-jcm-08-00657],[@B52-jcm-08-00657],[@B53-jcm-08-00657],[@B54-jcm-08-00657],[@B56-jcm-08-00657],[@B57-jcm-08-00657],[@B58-jcm-08-00657],[@B59-jcm-08-00657],[@B60-jcm-08-00657],[@B62-jcm-08-00657],[@B63-jcm-08-00657],[@B64-jcm-08-00657],[@B65-jcm-08-00657],[@B66-jcm-08-00657],[@B68-jcm-08-00657],[@B69-jcm-08-00657],[@B70-jcm-08-00657],[@B71-jcm-08-00657],[@B72-jcm-08-00657],[@B73-jcm-08-00657]\] evaluating the performance of sPGA for the diagnosis of GC, four studies \[[@B21-jcm-08-00657],[@B27-jcm-08-00657],[@B45-jcm-08-00657],[@B73-jcm-08-00657]\] for the diagnosis of gastric dysplasia, and four studies \[[@B55-jcm-08-00657],[@B61-jcm-08-00657],[@B67-jcm-08-00657],[@B71-jcm-08-00657]\] for the diagnosis of gastric neoplasm, were incorporated in the quantitative synthesis.

Among the 38 studies for the diagnosis of GC, 28 studies \[[@B35-jcm-08-00657],[@B36-jcm-08-00657],[@B37-jcm-08-00657],[@B38-jcm-08-00657],[@B40-jcm-08-00657],[@B41-jcm-08-00657],[@B42-jcm-08-00657],[@B43-jcm-08-00657],[@B46-jcm-08-00657],[@B48-jcm-08-00657],[@B49-jcm-08-00657],[@B50-jcm-08-00657],[@B51-jcm-08-00657],[@B53-jcm-08-00657],[@B54-jcm-08-00657],[@B56-jcm-08-00657],[@B57-jcm-08-00657],[@B58-jcm-08-00657],[@B59-jcm-08-00657],[@B60-jcm-08-00657],[@B62-jcm-08-00657],[@B63-jcm-08-00657],[@B65-jcm-08-00657],[@B66-jcm-08-00657],[@B70-jcm-08-00657],[@B71-jcm-08-00657],[@B72-jcm-08-00657],[@B73-jcm-08-00657]\] adopted the cut-off standard of PG I ≤70 ng/mL and PG I/PG II ratio ≤3, 11 studies \[[@B26-jcm-08-00657],[@B38-jcm-08-00657],[@B39-jcm-08-00657],[@B44-jcm-08-00657],[@B45-jcm-08-00657],[@B47-jcm-08-00657],[@B52-jcm-08-00657],[@B57-jcm-08-00657],[@B65-jcm-08-00657],[@B68-jcm-08-00657],[@B69-jcm-08-00657]\] adopted the cut-off standard of PG I/PG II ratio ≤3, and only six studies \[[@B34-jcm-08-00657],[@B45-jcm-08-00657],[@B57-jcm-08-00657],[@B64-jcm-08-00657],[@B65-jcm-08-00657],[@B69-jcm-08-00657]\] adopted the cut-off standard of PG I ≤70 ng/mL.

Among the 28 studies that adopted the cut-off standard of PG I ≤70 ng/mL and PG I/PG II ratio ≤3, two studies \[[@B46-jcm-08-00657],[@B51-jcm-08-00657]\] evaluated diagnostic performance for sPGA based on same population with slightly different inclusion criteria. Therefore, to avoid dependence issue from single population-based multiple outcomes, the study with larger population \[[@B46-jcm-08-00657]\] was included in the meta-analysis as a representative outcome. Finally, 27 studies were included for the diagnosis of GC with the cut-off standard of PG I ≤70 ng/mL and PG I/PG II ratio ≤3.

3.2. Characteristics of the Included Studies {#sec3dot2-jcm-08-00657}
--------------------------------------------

From the 14 studies \[[@B20-jcm-08-00657],[@B21-jcm-08-00657],[@B22-jcm-08-00657],[@B23-jcm-08-00657],[@B24-jcm-08-00657],[@B25-jcm-08-00657],[@B26-jcm-08-00657],[@B27-jcm-08-00657],[@B28-jcm-08-00657],[@B29-jcm-08-00657],[@B30-jcm-08-00657],[@B31-jcm-08-00657],[@B32-jcm-08-00657],[@B33-jcm-08-00657]\] for the diagnosis of CAG, we identified a total of 5541 patients (2220 patients with CAG vs. 3321 patients without CAG). Among them, 11 \[[@B20-jcm-08-00657],[@B22-jcm-08-00657],[@B23-jcm-08-00657],[@B24-jcm-08-00657],[@B25-jcm-08-00657],[@B26-jcm-08-00657],[@B27-jcm-08-00657],[@B28-jcm-08-00657],[@B30-jcm-08-00657],[@B31-jcm-08-00657],[@B32-jcm-08-00657]\] were case-control studies, whereas two \[[@B21-jcm-08-00657],[@B33-jcm-08-00657]\] were cross-sectional studies and only one \[[@B29-jcm-08-00657]\] was cohort study. Seven studies \[[@B20-jcm-08-00657],[@B24-jcm-08-00657],[@B28-jcm-08-00657],[@B29-jcm-08-00657],[@B30-jcm-08-00657],[@B31-jcm-08-00657],[@B33-jcm-08-00657]\] were conducted in Asia, whereas the remaining studies were conducted in Europe \[[@B21-jcm-08-00657],[@B22-jcm-08-00657],[@B26-jcm-08-00657],[@B27-jcm-08-00657],[@B32-jcm-08-00657]\] and South America \[[@B23-jcm-08-00657]\]. In 2009, Leja M et al. \[[@B25-jcm-08-00657]\] reported enrollment of the population in Latvia, Lithuania, and Taiwan as an international study setting. The mean age of the enrolled population ranged from 43.6 to 66.3 years. Male predominance was detected in four studies \[[@B24-jcm-08-00657],[@B26-jcm-08-00657],[@B28-jcm-08-00657],[@B31-jcm-08-00657]\], whereas the remaining studies showed female predominance. For detection method of sPGA, most studies used enzyme-linked immunosorbent assay (ELISA), whereas three studies \[[@B28-jcm-08-00657],[@B29-jcm-08-00657],[@B32-jcm-08-00657]\] used latex-enhanced turbidimetric immunoassay (L-TIA) and two studies \[[@B20-jcm-08-00657],[@B26-jcm-08-00657]\] deployed radioimmunoassay (RIA) ([Table 3](#jcm-08-00657-t003){ref-type="table"}).

From the 43 studies \[[@B21-jcm-08-00657],[@B26-jcm-08-00657],[@B27-jcm-08-00657],[@B34-jcm-08-00657],[@B35-jcm-08-00657],[@B36-jcm-08-00657],[@B37-jcm-08-00657],[@B38-jcm-08-00657],[@B39-jcm-08-00657],[@B40-jcm-08-00657],[@B41-jcm-08-00657],[@B42-jcm-08-00657],[@B43-jcm-08-00657],[@B44-jcm-08-00657],[@B45-jcm-08-00657],[@B46-jcm-08-00657],[@B47-jcm-08-00657],[@B48-jcm-08-00657],[@B49-jcm-08-00657],[@B50-jcm-08-00657],[@B51-jcm-08-00657],[@B52-jcm-08-00657],[@B53-jcm-08-00657],[@B54-jcm-08-00657],[@B55-jcm-08-00657],[@B56-jcm-08-00657],[@B57-jcm-08-00657],[@B58-jcm-08-00657],[@B59-jcm-08-00657],[@B60-jcm-08-00657],[@B61-jcm-08-00657],[@B62-jcm-08-00657],[@B63-jcm-08-00657],[@B64-jcm-08-00657],[@B65-jcm-08-00657],[@B66-jcm-08-00657],[@B67-jcm-08-00657],[@B68-jcm-08-00657],[@B69-jcm-08-00657],[@B70-jcm-08-00657],[@B71-jcm-08-00657],[@B72-jcm-08-00657],[@B73-jcm-08-00657]\] for the diagnosis of gastric neoplasm, we identified a total of 114,448 patients (4689 patients with GC, 430 patients with neoplasm, 130 patients with dysplasia vs. 109,199 patients without gastric neoplasm). Among them, 20 \[[@B26-jcm-08-00657],[@B27-jcm-08-00657],[@B34-jcm-08-00657],[@B36-jcm-08-00657],[@B37-jcm-08-00657],[@B40-jcm-08-00657],[@B43-jcm-08-00657],[@B44-jcm-08-00657],[@B45-jcm-08-00657],[@B54-jcm-08-00657],[@B55-jcm-08-00657],[@B56-jcm-08-00657],[@B57-jcm-08-00657],[@B58-jcm-08-00657],[@B61-jcm-08-00657],[@B62-jcm-08-00657],[@B64-jcm-08-00657],[@B67-jcm-08-00657],[@B68-jcm-08-00657],[@B72-jcm-08-00657]\] were case--control studies, whereas 18 \[[@B35-jcm-08-00657],[@B39-jcm-08-00657],[@B41-jcm-08-00657],[@B42-jcm-08-00657],[@B46-jcm-08-00657],[@B47-jcm-08-00657],[@B48-jcm-08-00657],[@B49-jcm-08-00657],[@B50-jcm-08-00657],[@B51-jcm-08-00657],[@B53-jcm-08-00657],[@B59-jcm-08-00657],[@B60-jcm-08-00657],[@B63-jcm-08-00657],[@B66-jcm-08-00657],[@B69-jcm-08-00657],[@B70-jcm-08-00657],[@B71-jcm-08-00657]\] were cohort studies, and only five \[[@B21-jcm-08-00657],[@B38-jcm-08-00657],[@B52-jcm-08-00657],[@B65-jcm-08-00657],[@B73-jcm-08-00657]\] were cross-sectional studies. Six studies \[[@B21-jcm-08-00657],[@B26-jcm-08-00657],[@B27-jcm-08-00657],[@B59-jcm-08-00657],[@B70-jcm-08-00657],[@B73-jcm-08-00657]\] were conducted in Europe, whereas the remaining 37 studies were conducted in Asia. The mean age of the enrolled population ranged from 33.4 to 68.2 years. Most of the studies showed male predominance except 11 studies \[[@B21-jcm-08-00657],[@B27-jcm-08-00657],[@B38-jcm-08-00657],[@B42-jcm-08-00657],[@B53-jcm-08-00657],[@B59-jcm-08-00657],[@B60-jcm-08-00657],[@B66-jcm-08-00657],[@B67-jcm-08-00657],[@B70-jcm-08-00657],[@B73-jcm-08-00657]\] showing female predominance. For detection of sPGA, most studies used RIA, whereas nine studies \[[@B21-jcm-08-00657],[@B27-jcm-08-00657],[@B50-jcm-08-00657],[@B54-jcm-08-00657],[@B59-jcm-08-00657],[@B64-jcm-08-00657],[@B65-jcm-08-00657],[@B69-jcm-08-00657],[@B70-jcm-08-00657]\] used ELISA, eight studies \[[@B45-jcm-08-00657],[@B52-jcm-08-00657],[@B55-jcm-08-00657],[@B61-jcm-08-00657],[@B67-jcm-08-00657],[@B71-jcm-08-00657],[@B72-jcm-08-00657],[@B73-jcm-08-00657]\] used L-TIA, four studies \[[@B49-jcm-08-00657],[@B56-jcm-08-00657],[@B57-jcm-08-00657],[@B62-jcm-08-00657]\] used chemiluminescent immunoassay (CLIA), two studies \[[@B43-jcm-08-00657],[@B68-jcm-08-00657]\] used enzyme immunoassay (EIA), and one study \[[@B48-jcm-08-00657]\] used either RIA or L-TIA ([Table 4](#jcm-08-00657-t004){ref-type="table"}).

3.3. Methodological Quality of the Include Studies {#sec3dot3-jcm-08-00657}
--------------------------------------------------

Methodological qualities of the included studies were similar for the diagnosis of CAG except for five studies. Most of the studies used histological diagnosis as a reference standard of CAG diagnosis; however, three studies \[[@B20-jcm-08-00657],[@B28-jcm-08-00657],[@B31-jcm-08-00657]\] deployed endoscopic diagnosis (visual inspection) as a reference standard of CAG diagnosis. One study \[[@B21-jcm-08-00657]\] included only high-risk patients, such as patients with severe CAG, IM, and dysplasia, excluding the healthy population. Another study \[[@B33-jcm-08-00657]\] also included high-risk patients as a population for reference standard. These five studies for the diagnosis of CAG were rated as "high-risk" in at least one of the seven domains ([Figure 2](#jcm-08-00657-f002){ref-type="fig"}).

Methodological qualities of the included studies were similar for the diagnosis of gastric neoplasm except for 13 studies. Ideally, all the patients should be tested with the same reference standard method (endoscopy). However, seven studies \[[@B35-jcm-08-00657],[@B39-jcm-08-00657],[@B46-jcm-08-00657],[@B47-jcm-08-00657],[@B49-jcm-08-00657],[@B51-jcm-08-00657],[@B63-jcm-08-00657]\] performed endoscopy to diagnose gastric neoplasm only for patients with positive sPGA or positive double-contrast barium X-ray introducing partial verification bias. One study \[[@B48-jcm-08-00657]\] conducted endoscopy every 2 years for patients with positive sPGA and every 5 years for patients with negative sPGA, adopting different standards of reference test (differential verification bias).

Five studies \[[@B39-jcm-08-00657],[@B46-jcm-08-00657],[@B47-jcm-08-00657],[@B51-jcm-08-00657],[@B63-jcm-08-00657]\] included only male patients, one study \[[@B44-jcm-08-00657]\] included only patients with *H. pylori* infection, two studies \[[@B57-jcm-08-00657],[@B72-jcm-08-00657]\] included only patients with early GC, and one study \[[@B58-jcm-08-00657]\] included only patients with diffuse-type GC.

Two studies \[[@B46-jcm-08-00657],[@B51-jcm-08-00657]\] evaluated diagnostic performance of sPGA based on a same population with slightly different inclusion criteria and another two studies \[[@B46-jcm-08-00657],[@B47-jcm-08-00657]\] also evaluated diagnostic performance based on a same population using different cut-off values. Therefore, these studies were ranked as "high-risk" for the applicability concerns.

Since most of the studies were case-control studies, they were not ranked as "high-risk". A total of 13 abovementioned studies for the diagnosis of gastric neoplasm were rated as "high-risk" in at least one of the seven domains ([Figure 3](#jcm-08-00657-f003){ref-type="fig"}).

3.4. DTA of sPGA in CAG {#sec3dot4-jcm-08-00657}
-----------------------

Values for sensitivity, specificity, PLR, NLR, DOR, and area under the curve (AUC) with 95% CI for the cut-off value of PG I ≤70 ng/mL and PG I/PG II ratio ≤3 for CAG diagnosis were 0.59 (95% CI: 0.38--0.78), 0.89 (0.70--0.97), 5.5 (2.3--13.0), 0.46 (0.30--0.69), 12 (6--25), and 0.81 (0.77--0.84), respectively ([Table 5](#jcm-08-00657-t005){ref-type="table"}, [Figure 4](#jcm-08-00657-f004){ref-type="fig"}A). The SROC curve with 95% confidence region and prediction region is illustrated in [Figure 5](#jcm-08-00657-f005){ref-type="fig"}A. To investigate the clinical utility of sPGA, Fagan's nomogram was generated. Assuming 20% prevalence of CAG (prior probability), Fagan's nomogram shows that the posterior probability of CAG is 58% if patients are diagnosed as positive, and the posterior probability of CAG is 10% if patients are diagnosed as negative according to the sPGA with the cut-off value of PG I ≤70 ng/mL and PG I/PG II ratio ≤3 ([Figure 6](#jcm-08-00657-f006){ref-type="fig"}A).

Values of sensitivity, specificity, PLR, NLR, DOR, and AUC with 95% CI for the cut-off value of PG I/PG II ratio ≤3 for CAG diagnosis were 0.50 (0.28--0.72), 0.94 (0.82--0.98), 7.8 (3.3--18.1), 0.53 (0.34--0.82), 15 (6--37), and 0.85 (0.81--0.88), respectively ([Table 5](#jcm-08-00657-t005){ref-type="table"}, [Figure 4](#jcm-08-00657-f004){ref-type="fig"}B). The SROC curve with 95% confidence region and prediction region is illustrated in [Figure 5](#jcm-08-00657-f005){ref-type="fig"}B. Fagan's nomogram shows that the posterior probability of CAG is 66% if patients are diagnosed as positive, and the posterior probability of CAG is 12% if patients are diagnosed as negative according to the sPGA with the cut-off value of PG I/PG II ratio ≤3 ([Figure 6](#jcm-08-00657-f006){ref-type="fig"}B).

3.5. DTA of sPGA in GC {#sec3dot5-jcm-08-00657}
----------------------

Since the minimum number of studies required for the quantitative analysis is four, DTA summary of sPGA in dysplasia or neoplasm was not calculated with a specific cut-off standard (only two or three studies were included with a specific cut-off value) ([Figure 1](#jcm-08-00657-f001){ref-type="fig"}).

Sensitivity, specificity, PLR, NLR, DOR and AUC with 95% CI for the cut-off value of PG I ≤70 ng/mL and PG I/PG II ratio ≤3 for GC diagnosis were 0.59 (0.50--0.67), 0.73 (0.64--0.81), 2.2 (1.7--2.9), 0.56 (0.46--0.68), 4 (3--6), and 0.70 (0.66--0.74), respectively ([Table 6](#jcm-08-00657-t006){ref-type="table"}, [Figure 7](#jcm-08-00657-f007){ref-type="fig"}A). The SROC curve with 95% confidence region and prediction region is illustrated in [Figure 8](#jcm-08-00657-f008){ref-type="fig"}A. Assuming 20% prevalence of GC (prior probability), Fagan's nomogram shows that the posterior probability of GC is 36% if patients are diagnosed as positive, and the posterior probability of GC is 13% if patients are diagnosed as negative according to the sPGA with the cut-off value of PG I ≤70 ng/mL and PG I/PG II ratio ≤3 ([Figure 9](#jcm-08-00657-f009){ref-type="fig"}A).

Values for sensitivity, specificity, PLR, NLR, DOR, and AUC with 95% CI for the cut-off value of PG I ≤70 ng/mL for GC diagnosis were 0.62 (0.38--0.82), 0.57 (0.32--0.79), 1.4 (0.9--2.3), 0.67 (0.40--1.11), 2 (1--5), and 0.63 (0.58--0.67), respectively ([Table 6](#jcm-08-00657-t006){ref-type="table"}, [Figure 7](#jcm-08-00657-f007){ref-type="fig"}B). The SROC curve with 95% confidence region and prediction region is illustrated in [Figure 8](#jcm-08-00657-f008){ref-type="fig"}B. Fagan's nomogram shows that the posterior probability of GC is 26% if patients are diagnosed as positive, and the posterior probability of GC is 14% if patients are diagnosed as negative according to the sPGA with the cut-off value of PG I ≤70 ng/mL ([Figure 9](#jcm-08-00657-f009){ref-type="fig"}B).

Values for sensitivity, specificity, PLR, NLR, DOR, and AUC with 95% CI for the cut-off value of PG I/PG II ratio ≤3 for GC diagnosis were 0.56 (0.35--0.75), 0.78 (0.62--0.88), 2.5 (1.7--3.7), 0.56 (0.39--0.81), 4 (3--8), and 0.74 (0.70--0.78), respectively ([Table 6](#jcm-08-00657-t006){ref-type="table"}, [Figure 7](#jcm-08-00657-f007){ref-type="fig"}C). The SROC curve with 95% confidence region and prediction region is illustrated in [Figure 8](#jcm-08-00657-f008){ref-type="fig"}C. Fagan's normogram shows that the posterior probability of GC is 39% if patients are diagnosed as positive, and the posterior probability of GC is 12% if patients are diagnosed as negative according to the sPGA with the cut-off value of PG I/PG II ratio ≤3 ([Figure 9](#jcm-08-00657-f009){ref-type="fig"}C).

3.6. Exploring Heterogeneity with Meta-Regression and Subgroup Analysis of sPGA in CAG {#sec3dot6-jcm-08-00657}
--------------------------------------------------------------------------------------

For the diagnosis of CAG with the cut-off value of PG I ≤70 ng/mL and PG I/PG II ratio ≤3, the SROC curve was symmetric ([Figure 5](#jcm-08-00657-f005){ref-type="fig"}A). We observed a negative correlation coefficient between logit transformed sensitivity and specificity (−0.92) and asymmetry parameter, β, with non-significant *p* value (*p =* 0.14) indicating no heterogeneity among studies. However, 95% prediction region in the SROC curve was wide, and age (*p =* 0.01) and methodological quality of the included studies (*p =* 0.01) were found to be the source of heterogeneity in meta-regression. Subgroup analyses according to the modifiers of heterogeneity showed lower AUCs in studies with a younger population (\<60 years) and high methodological quality ([Table 5](#jcm-08-00657-t005){ref-type="table"}).

For the diagnosis of CAG with the cut-off value of PG I/PG II ratio ≤3, the SROC curve was symmetric ([Figure 5](#jcm-08-00657-f005){ref-type="fig"}B). We observed a negative correlation coefficient between logit transformed sensitivity and specificity (−0.72) and asymmetry parameter, β, with non-significant *p* value (*p =* 0.70), indicating no heterogeneity among studies. However, the 95% prediction region in the SROC curve was wide, and ethnicity (*p =* 0.02), age (*p =* 0.03), methodological quality of included studies (*p =* 0.01), and total number of patients (*p =* 0.05) were found to be the source of heterogeneity in meta-regression. Subgroup analyses according to the modifiers of heterogeneity showed lower AUCs in studies with a younger population (\<60 years), an Asian population, low methodological quality, and higher number of included patients (≥1000) ([Table 5](#jcm-08-00657-t005){ref-type="table"}).

3.7. Exploring Heterogeneity with Meta-Regression and Subgroup Analysis of sPGA in GC {#sec3dot7-jcm-08-00657}
-------------------------------------------------------------------------------------

For the diagnosis of GC with the cut-off value of PG I ≤70 ng/mL and PG I/PG II ratio ≤3, SROC curve was symmetric ([Figure 8](#jcm-08-00657-f008){ref-type="fig"}A). We observed a negative correlation coefficient between logit transformed sensitivity and specificity (−0.38) and asymmetry parameter, β, with non-significant *p* value (*p =* 0.26), indicating no heterogeneity among studies. However, 95% prediction region in SROC curve was wide and ethnicity (*p =* 0.02), published year (*p =* 0.01), and total number of patients (*p =* 0.01) were found to be the source of heterogeneity in meta-regression. Subgroup analyses according to the modifiers of heterogeneity showed lower AUCs in studies with Western population, more recent publications (2010--2018 vs. 1995--2009) and lower number of included patients (\<1000) ([Table 6](#jcm-08-00657-t006){ref-type="table"}).

For the diagnosis of GC with the cut-off value of PG I ≤70 ng/mL, the SROC curve was symmetric ([Figure 8](#jcm-08-00657-f008){ref-type="fig"}B). We observed a negative correlation coefficient between logit transformed sensitivity and specificity (−0.61) and asymmetry parameter, β, with non-significant *p* value (*p =* 0.92), indicating no heterogeneity among studies. However, 95% prediction region in the SROC curve was wide and methodological quality of included studies (*p =* 0.05), detection method of sPGA (*p* \<0.01), and total number of patients (*p* \<0.01) were found to be the source of heterogeneity in meta-regression. Subgroup analyses according to the modifiers of heterogeneity was only possible for methodological quality, because the number of subgroups classified according to the other modifiers was lower than four. Subgroup analysis showed lower AUCs in studies with high methodological quality ([Table 6](#jcm-08-00657-t006){ref-type="table"}).

For the diagnosis of GC with the cut-off value of PG I/PG II ratio ≤3, the SROC curve was symmetric ([Figure 8](#jcm-08-00657-f008){ref-type="fig"}C). We observed a negative correlation coefficient between logit transformed sensitivity and specificity (−0.83) and asymmetry parameter, β, with non-significant *p* value (*p =* 0.57), indicating no heterogeneity among studies. Only ethnicity (*p* \<0.01) was found to be the source of heterogeneity in meta-regression. Subgroup analyses according to the modifier of heterogeneity showed lower AUCs in studies with Asian populations ([Table 6](#jcm-08-00657-t006){ref-type="table"}).

3.8. Publication Bias {#sec3dot8-jcm-08-00657}
---------------------

Publication bias was not evaluated for diagnosis of CAG, as fewer than 10 studies on this subject were included with any cut-off values.

For the diagnosis of GC, 27 studies were included with cut-off value of PG I ≤70 ng/mL and PG I/PG II ratio ≤3. Deeks' funnel plot asymmetry test showed no evidence of publication bias (*p =* 0.71) ([Figure 10](#jcm-08-00657-f010){ref-type="fig"}A). Publication bias was not evaluated for cut-off of PG I ≤70 ng/mL, as only six studies were included with this cut-off value. Eleven studies were included with cut-off of PG I/PG II ratio ≤3. Although Deeks' funnel plot asymmetry test for 11 studies with a cut-off value of PG I/PG II ratio ≤3 showed a *p* value of 0.02, indicating publication bias, the plot was symmetrical with respect to the regression line ([Figure 10](#jcm-08-00657-f010){ref-type="fig"}B).

4. Discussion {#sec4-jcm-08-00657}
=============

There are two main types of pepsinogen (PG), namely PG I and PG II, which are proenzymes of pepsin, an endoproteinase present in the gastric juice \[[@B21-jcm-08-00657]\]. PG I is secreted mainly by chief cells in the fundic glands of the stomach fundus and body, whereas PG II is secreted by all the gastric glands and the proximal duodenal mucosa (Brunner's glands) \[[@B5-jcm-08-00657],[@B21-jcm-08-00657],[@B74-jcm-08-00657],[@B75-jcm-08-00657]\]. The secretion ability of gastric mucosa is usually intact in the case of no infection or acute *H. pylori* infection \[[@B75-jcm-08-00657]\]. However, when chronic *H. pylori* infection with CAG extends from antrum to corpus of stomach, chief cells are replaced by pyloric glands \[[@B7-jcm-08-00657]\]. Therefore, concentration of serum PG I decreases due to the damaged secretion ability of gastric mucosa, whereas the concentration of PG II remains relatively intact, leading to a low PG I/PG II ratio and this value reflects the severity of CAG \[[@B4-jcm-08-00657],[@B7-jcm-08-00657],[@B75-jcm-08-00657]\].

Although various cut-off values have been suggested, PG I ≤70 ng/mL and PG I/PG II ratio ≤3 have been proposed for the prediction of CAG or GC \[[@B4-jcm-08-00657],[@B8-jcm-08-00657]\]. However, previous meta-analyses presented only pooled outcomes, which cannot determine the diagnostic validity of sPGA with cut-off value of PG I ≤70 ng/mL and PG I/PG II ratio ≤3 \[[@B9-jcm-08-00657],[@B10-jcm-08-00657]\], although no threshold effect was detected \[[@B9-jcm-08-00657]\]. Moreover, the meta-analysis determined publication bias with Begg's test, which is inappropriate for DTA because of type I error inflation \[[@B9-jcm-08-00657]\]. Serum concentration of gastrin, which is produced and secreted primarily by the G cells in antrum, is increased when the corpus mucosa is predominantly involved, and decreased with antral predominant gastric atrophy \[[@B5-jcm-08-00657],[@B75-jcm-08-00657]\]. Combined efficacy of sPGA with *H. pylori* antibody \[[@B11-jcm-08-00657]\] and/or gastrin-17 \[[@B12-jcm-08-00657],[@B13-jcm-08-00657]\] has been indicated for the prediction of gastric cancer \[[@B11-jcm-08-00657]\] and CAG \[[@B12-jcm-08-00657],[@B13-jcm-08-00657]\], and it is mainly used in Europe (as panel test). However, sPGA is preferable to serum gastrin measurement because sPGA reflects gastric mucosal status better \[[@B75-jcm-08-00657]\]. Moreover, previous meta-analyses could not determine the diagnostic validity of sPGA alone \[[@B11-jcm-08-00657],[@B12-jcm-08-00657],[@B13-jcm-08-00657]\]. Although previous meta-analyses, published in 2004 and 2006, reported diagnostic validity of sPGA with cut-off value of PG I ≤70 ng/mL and PG I/PG II ratio ≤3, these studies cannot reflect recently published data and had several methodological pitfalls \[[@B8-jcm-08-00657],[@B14-jcm-08-00657]\] ([Table 1](#jcm-08-00657-t001){ref-type="table"}).

The results of our study confirm that the performance of sPGA is better for the diagnosis of CAG than GC, and sPGA has potential for CAG or GC screening (triage test) considering its high specificity ([Table 5](#jcm-08-00657-t005){ref-type="table"} and [Table 6](#jcm-08-00657-t006){ref-type="table"}). Another finding of this study is the diagnostic validity of sPGA with cut-off value of PG I/PG II ratio ≤3. Although direct comparison of DOR does not have significant implications, the DTA of sPGA with cut-off value of PG I/PG II ratio ≤3 was similar to that with cut-off value of PG I ≤70 ng/mL and PG I/PG II ratio ≤3 ([Table 5](#jcm-08-00657-t005){ref-type="table"} and [Table 6](#jcm-08-00657-t006){ref-type="table"}). A recent study also indicated that the PG I/PG II ratio is one of the stomach-specific circulating biomarkers for GC risk assessment \[[@B69-jcm-08-00657]\]. It is also known that sPGA is a cost-effective diagnostic test and useful to reduce the intestinal-type GC, especially for high-risk populations \[[@B76-jcm-08-00657],[@B77-jcm-08-00657]\]. Considering the non-invasiveness and easily interpretable characteristics, the results of this study indicates the utility of sPGA as a population-based screening tool for CAG or GC.

Compared to the previous meta-analyses that combined the diagnostic values with various cut-off standards in a single outcome, the results of this study showed slightly lower diagnostic values (AUC for the diagnosis of CAG: 0.81 vs. 0.85/AUC for the diagnosis of GC: 0.70 vs. 0.76/DOR for the diagnosis of GC: 4 vs. 5.41), indicating overestimation of diagnostic validity in previous studies \[[@B9-jcm-08-00657],[@B10-jcm-08-00657]\].

In terms of the reasons of heterogeneity, subgroup analyses showed decreased *I^2^* values in high-quality studies with cut-off value of PG I ≤70 ng/mL and PG I/PG II ratio ≤3 for the diagnosis of CAG compared to those of main analysis (*I^2^* of sensitivity: 96.4% to 61.5%, *I^2^* of specificity: 96.1% to 88.6%) ([Figure 4](#jcm-08-00657-f004){ref-type="fig"} and [Table 5](#jcm-08-00657-t005){ref-type="table"}). In the subgroup analyses with a cut-off value of PG I/PG II ratio ≤3 for the diagnosis of CAG, high-quality studies (*I^2^* of sensitivity: 98.3% to 88.5%, *I^2^* of specificity: 98.2% to 74.2%) and a Western population (*I^2^* of sensitivity: 98.3% to 85.1%, *I^2^* of specificity: 98.2% to 80%) also showed decreased *I^2^* values compared to those of main analysis, indicating needs for high-quality studies with a Western population to enhance the evidence level in this topic. Although studies with Western population showed slightly higher AUC (0.88 vs. 0.85) than pooled AUC, the value is closer to that of high-quality studies subgroup (0.92), indicating it is not an overestimation, rather we need more Western population data to enhance the level of evidence. In [Table 6](#jcm-08-00657-t006){ref-type="table"}, recently published subgroup showed much lower AUC (0.61 vs. 0.76) than that of old publications; however, the AUC of recently published subgroup was closer to that of high-quality subgroup (0.68; data not shown because it was not a source of heterogeneity in meta-regression), indicating overestimation of older publications. There was a change in diagnostic values according to the modifiers in the subgroup analyses for the diagnosis of GC; however, such decrease of *I^2^* values in the subgroup analyses was not detected ([Table 6](#jcm-08-00657-t006){ref-type="table"}) (data about *I^2^* not shown in the results section).

The distribution of CAG or IM (known as pre-malignant or high-risk lesions of GC) in entire population affects the determination of optimal cut-off value of sPGA (spectrum bias). In our meta-analysis, a study by Dinis-Ribeiro et al. \[[@B21-jcm-08-00657]\] included high-risk patients of GC, such as those with AG, IM, or dysplasia, excluding the healthy population, and showed higher sensitivity compared to that of pooled analysis with cut-off of PG I/PG II ratio ≤3 (0.66 vs. 0.50) ([Table 5](#jcm-08-00657-t005){ref-type="table"}). A previous study by Valli De Re et al. \[[@B78-jcm-08-00657]\] also included high-risk patients, such as first-degree relatives of patients with GC or CAG, and showed high sensitivity and specificity of 0.96 and 0.93 for the prediction of Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) stage ≥2 with cut-off of PG I ≤47.9 ng/mL. The proposed cut-off of PG I was lower than 70 ng/mL because they included a high-risk population. However, they proposed algorithm approach of using gastrin-17 first, because they included high-risk patients and gastrin-17 showed highest discrimination capacity of CAG among proposed biomarkers. For the next-step, they recommended using PG I ≤47.9 ng/mL for the prediction of OLGIM stage ≥2. PG I generally shows a low level in CAG; however, if an optimal cut-off should be determined in a high-risk population, lower cut-off value might be required. A combination with a marker, such as gastrin-17, which shows high discriminative performance of CAG, could be considered.

The present study rigorously investigated the diagnostic validity of sPGA with well-known cut-off value of PG I ≤70 ng/mL and/or PG I/PG II ratio ≤3 for the diagnosis of CAG or GC, excluding threshold effect. However, the study has several limitations. Firstly, a relatively small number of studies were enrolled with cut-off value of PG I ≤70 ng/mL or PG I/PG II ratio ≤3 compared to the combination of both values. Secondly, potential publication bias was suspected in the diagnosis of GC with cut-off value of PG I/PG II ratio ≤3 (Deeks' funnel plot asymmetry test showed *p* value of 0.02, although the plot showed symmetrical shape), probably due to relatively small number of enrolled studies (*n =* 11) ([Figure 10](#jcm-08-00657-f010){ref-type="fig"}B). Thirdly, substantial heterogeneity among studies were suspected, although rigorous subgroup analyses were performed and interpreted. Fourthly, this meta-analysis included many case--control studies, which easily overestimate the diagnostic validity of the index test. Fifthly, the diagnostic validity of sPGA is known to be associated with the smoking, *H. pylori* infection status, or the proportion of diffuse-type GC of the enrolled population \[[@B79-jcm-08-00657]\]. However, this information was presented only in small portion of enrolled studies, limiting further analysis.

In conclusion, sPGA has the potential for use as a CAG or GC screening (triage test). Considering the heterogeneity among studies found in this analysis, high-quality studies based on Western populations could enhance the evidence level in this topic. Most importantly, considering that the usefulness of sPGA may be different between countries, this biomarker should be validated before practically using it for the screening of CAG or GC, because the enrolled studies were conducted in only a few countries.
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sPGA, serum pepsinogen assay; PG, pepsinogen; CAG, chronic atrophic gastritis; GC, gastric cancer; IM, intestinal metaplasia; DTA, diagnostic test accuracy; TP, true positive; FP, false positive; TN, true negative; FN, false negative; PPV, positive predictive value; NPV, negative predictive value; PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic odds ratio; QUADAS-2, Quality Assessment of Diagnostic Accuracy Studies-2; CI, confidence interval; HSROC, hierarchical summary receiver operating characteristic; ELISA, enzyme-linked immunosorbent assay; L-TIA, latex-enhanced turbidimetric immunoassay; RIA, radioimmunoassay; CLIA, chemiluminescent immunoassay; EIA, enzyme immunoassay; AUC, area under the curve.

###### 

Flow diagram of the identification of relevant studies. (**A**) For the diagnosis of CAG, (**B**) For the diagnosis of gastric neoplasm. PG, pepsinogen; CAG, chronic atrophic gastritis.
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![QUADAS-2 for the assessment of the methodological qualities of all the enrolled studies for the diagnosis of CAG. (+) denotes low risk of bias, (?) denotes unclear risk of bias, (--) denotes high risk of bias. QUADAS-2, Quality Assessment of Diagnostic Accuracy Studies-2; CAG, chronic atrophic gastritis.](jcm-08-00657-g002){#jcm-08-00657-f002}

![QUADAS-2 for the assessment of the methodological qualities of all the enrolled studies for the diagnosis of gastric neoplasm. (+) denotes low risk of bias, (?) denotes unclear risk of bias, (--) denotes high risk of bias. QUADAS-2, Quality Assessment of Diagnostic Accuracy Studies-2.](jcm-08-00657-g003){#jcm-08-00657-f003}

![Forest plots of sensitivity and specificity for the diagnosis of CAG. (**A**) cut-off value with PG I ≤70 ng/mL and PG I/PG II ratio ≤3, (**B**) cut-off value with PG I/PG II ratio ≤3. CAG, chronic atrophic gastritis; PG, pepsinogen.](jcm-08-00657-g004){#jcm-08-00657-f004}

![SROC curve with 95% confidence region and prediction region for the diagnosis of CAG. (**A**) cut-off value with PG I ≤70 ng/mL and PG I/PG II ratio ≤3, (**B**) cut-off value with PG I/PG II ratio ≤3. SROC, summary receiver operating characteristic; CAG, chronic atrophic gastritis; PG, pepsinogen; SENS, sensitivity; SPEC, specificity; AUC, area under the curve.](jcm-08-00657-g005){#jcm-08-00657-f005}

![Fagan's normogram for the diagnosis of CAG. (**A**) cut-off value with PG I ≤70 ng/mL and PG I/PG II ratio ≤3, (**B**) cut-off value with PG I/PG II ratio ≤3. CAG, chronic atrophic gastritis; PG, pepsinogen; LR, likelihood raio.](jcm-08-00657-g006){#jcm-08-00657-f006}

###### 

Forest plots of sensitivity and specificity for the diagnosis of GC. (**A**) cut-off value with PG I ≤70 ng/mL and PG I/PG II ratio ≤3, (**B**) cut-off value with PG I ≤70 ng/mL, (**C**) cut-off value with PG I/PG II ratio ≤3. GC, gastric cancer; PG, pepsinogen.
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![SROC curve with 95% confidence region and prediction region for the diagnosis of GC. (**A**) cut-off value with PG I ≤70 ng/mL and PG I/PG II ratio ≤3, (**B**) cut-off value with PG I ≤70 ng/mL, (**C**) cut-off value with PG I/PG II ratio ≤3. SROC, summary receiver operating characteristic; GC, gastric cancer; PG, pepsinogen.](jcm-08-00657-g008){#jcm-08-00657-f008}

![Fagan's normogram for the diagnosis of GC. (**A**) cut-off value with PG I ≤70 ng/mL and PG I/PG II ratio ≤3, (**B**) cut-off value with PG I ≤70 ng/mL, (**C**) cut-off value with PG I/PG II ratio ≤3. GC, gastric cancer; PG, pepsinogen; LR, likelihood raio.](jcm-08-00657-g009){#jcm-08-00657-f009}

![Deek's funnel plot for the diagnosis of GC. (**A**) cut-off value with PG I ≤70 ng/mL and PG I/PG II ratio ≤3, (**B**) cut-off value with PG I/PG II ratio ≤3. GC, gastric cancer; PG, pepsinogen.](jcm-08-00657-g010){#jcm-08-00657-f010}
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###### 

Comparison of previous meta-analyses with current study.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameters                                       Current Study                                                               Dinis-Ribeiro et al. (2004) \[[@B8-jcm-08-00657]\]                                                                                                                                                                                           Miki et al. (2006) \[[@B14-jcm-08-00657]\]                                                                                                                                                                                                   Terasawa et al. (2014) \[[@B11-jcm-08-00657]\]                                                                                                                                 Huang et al. (2015) \[[@B9-jcm-08-00657]\]                                                                                                                                                                          Syrjänen et al. (2016) \[[@B13-jcm-08-00657]\]                                                                                                                    Zagari et al. (2017) \[[@B12-jcm-08-00657]\]       Liu et al. (2019) \[[@B10-jcm-08-00657]\]
  ------------------------------------------------ --------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------
  Number of included studies                       9 studies for the diagnosis of CAG and 17 studies for the diagnosis of GC   25 studies or book chapters for the diagnosis of GC                                                                                                                                                                                          42 studies for the diagnosis of GC                                                                                                                                                                                                           12 studies for the diagnosis of GC                                                                                                                                             16 studies for the diagnosis of CAG and 15 studies for the diagnosis of GC                                                                                                                                          27 studies for the diagnosis of CAG                                                                                                                               20 studies for the diagnosis of CAG                19 studies for the diagnosis of GC

  Main outcome                                     Diagnostic validity of sPGA                                                 Diagnostic validity of sPGA                                                                                                                                                                                                                  Diagnostic validity of sPGA                                                                                                                                                                                                                  Diagnostic validity of sPGA with *Helicobacter pylori* seropositivity                                                                                                          Diagnostic validity of sPGA                                                                                                                                                                                         Diagnostic validity of GastroPanel (pepsinogen, gastrin-17, anti *H. pylori* antibodies)                                                                          Diagnostic validity of GastroPanel                 

  Searching strategy                               PubMed, Embase, and the Cochrane Library (only studies in English)          PubMed and data reports from Japan (there was no information about searching keywords, the date of searching, the number of authors who performed searching, or how they managed disagreement or discrepancy of searching between authors)   PubMed and data reports from Japan (there was no information about searching keywords, the date of searching, the number of authors who performed searching, or how they managed disagreement or discrepancy of searching between authors)   PubMed, Web of Science, the Cochrane Library, and Japanese Medical Research Database (only studies in English or Japanese). The search was updated through citation-tracking   PubMed, Embase, and the CNKI (only studies in English or Chinese). Several articles were omitted.                                                                                                                   MEDLINE (no language limitation)                                                                                                                                  PubMed, Embase, Scopus, and the Cochrane Library   PubMed, Embase, the Cochrane Library, CNKI, WanFang, VIP, and CBM databases (only studies in English or Chinese). Several articles were omitted.

  Cut-off value                                    PG I ≤70 ng/mL and/or PG I/II ≤3                                            PG I ≤70 ng/mL and PG I/II ratio ≤3, PG I ≤50 ng/mL and PG I/II ratio ≤3, PG I ≤30 ng/mL and PG I/II ratio ≤2                                                                                                                                PG I ≤70 ng/mL and PG I/II ratio ≤3                                                                                                                                                                                                          PG I ≤70 ng/mL and PG I/II ratio ≤3                                                                                                                                            Diagnostic values with various cut-off standards were pooled in a single outcome                                                                                                                                                                                                                                                                                                                                                         Diagnostic values with various cut-off standards were pooled in a single outcome

  Inaccurate calculation (coding) of TP/FP/FN/TN                                                                               Unknown (crude value of TP/FP/FN/TN in each study is not described)                                                                                                                                                                          Unknown (crude value of TP/FP/FN/TN in each study is not described). Many studies with different cut-off values were coded as those of PG I ≤70 ng/mL and PG I/II ratio ≤3 (intrinsic cutoff effect was assumed)                             Not a meta-analysis with DTA. Hazard ratio was the effect size and conventional meta-analysis was done.                                                                        Detected in several studies                                                                                                                                                                                         Unknown. Not a meta-analysis with diagnostic test accuracy (DTA). Sensitivity and specificity of each study was pooled using conventional meta-analysis method.                                                      Detected in several studies

  Determination of heterogeneity                   Correlation\                                                                Chi-squared test (Cochrane Q statistic) with subgroup analysis according to the study population; (population-based study vs. GC screening in selected groups)                                                                               Chi-squared test (Cochrane Q statistic) (whether meta-regression was done or not is unknown)                                                                                                                                                 *I^2^* statistics                                                                                                                                                              *I^2^* statistics, correlation coefficient between sensitivity. Whether the correlation coefficient is between sensitivity and false positive rate or between sensitivity and specificity is not clearly defined.   *I^2^* statistics                                                                                                                                                 Visual\                                            *I^2^* statistics, Spearman correlation\
                                                   coefficient between the logarithm of the sensitivity and\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  examination of the forest plot and SROC curve      coefficient between the logarithm of the sensitivity and\
                                                   specificity, beta of HSROC model, visual\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     the logarithm of the (1---specificity), visual\
                                                   examination of the SROC curve                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 examination of the forest plot and SROC curve

  Quality assessment                               QUADAS-2                                                                    None                                                                                                                                                                                                                                         None                                                                                                                                                                                                                                         QUIPS-2, PROBAST                                                                                                                                                               QUADAS-2                                                                                                                                                                                                            None                                                                                                                                                              QUADAS-2                                           QUADAS

  Inaccurate coding for subgroup analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Study design was inaccurately coded in several studies.                                                                                                                                                                                                                                                                                                                                                                                  
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CAG, chronic atrophic gastritis; GC, gastric cancer; sPGA, serum pepsinogen assay; CNKI, China National Knowledge Infrastructure; VIP, Chongqing VIP Chinese Science and Technology Periodical Database; CBM, Chinese BioMedical Database; PG, pepsinogen; TP, true positive; FP, false positive; FN, false negative; TN, true negative; HSROC, hierarchical summary receiver operating characteristic; SROC, summary receiver operating characteristic; QUADAS, Quality Assessment of Diagnostic Accuracy Studies; QUIPS, Quality In Prognosis Studies; PROBAST, Prediction model Risk of Bias Assessment tool.

jcm-08-00657-t002_Table 2

###### 

Searching strategy to find the relevant articles.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **\<For CAG\>**
  **Database: MEDLINE (through PubMed)**
  \#1"gastric atrophy"\[tiab\] OR "atrophic gastritis"\[Mesh\]
  \#2"precancerous lesion"\[tiab\] OR "precancerous conditions"\[Mesh\]
  \#3\#1 OR \#2
  \#4"pepsinogen I"\[tiab\] OR "pepsinogen II"\[tiab\] OR "pepsinogen I/II"\[tiab\] OR "pepsinogens"\[Mesh\] OR "pepsinogen A"\[tiab\] OR "pepsinogen C"\[tiab\]
  \#5\#3 AND \#4
  \#6\#5 English\[Lang\]
  **Database: Embase**
  \#1'gastric atrophy':ab,ti,kw OR 'atrophic gastritis':ab,ti,kw OR 'atrophic gastritis'/exp
  \#2'precancerous lesion':ab,ti,kw OR 'precancerous condition':ab,ti,kw
  \#3\#1 OR \#2
  \#4'pepsinogen':ab,ti,kw OR 'pepsinogen I'/exp OR 'pepsinogen II'/exp OR 'pepsinogen I/II':ab,ti,kw OR 'pepsinogen A'/exp OR 'pepsinogen C'/exp
  \#5\#3 AND \#4
  \#6\#5 AND (\[article\]/lim OR \[article in press\]/lim OR \[review\]/lim) AND \[english\]/lim
  **Database: Cochrane Library**
  \#1gastric atrophy:ab,ti,kw
  \#2MeSH descriptor: \[atrophic gastritis\] explode all trees
  \#3precancerous lesion:ab,ti,kw
  \#4MeSH descriptor: \[precancerous conditions\] explode all trees
  \#5\#1 or \#2 or \#3 or \#4
  \#6pepsinogen I:ab,ti,kw or pepsinogen II:ab,ti,kw or pepsinogen A:ab,ti,kw or pepsinogen C:ab,ti,kw
  \#7MeSH descriptor: \[pepsinogens\] explode all trees
  \#8\#6 or \#7
  \#9\#5 and \#8
  **\<For gastric neoplasm\>**
  **Database: MEDLINE (through PubMed)**
  \#1"gastric cancer"\[tiab\] OR "gastric neoplasm"\[tiab\] OR "stomach cancer"\[tiab\] OR "stomach neoplasm"\[tiab\] OR "dysplasia"\[tiab\] OR "stomach neoplasms"\[Mesh\]
  \#2"pepsinogen I"\[tiab\] OR "pepsinogen II"\[tiab\] OR "pepsinogen I/II"\[tiab\] OR "pepsinogens"\[Mesh\] OR "pepsinogen A"\[tiab\] OR "pepsinogen C"\[tiab\]
  \#3\#1 AND \#2
  \#4\#3 English\[Lang\]
  **Database: Embase**
  \#1'gastric cancer':ab,ti,kw OR 'gastric neoplasm':ab,ti,kw OR 'dysplasia':ab,ti,kw OR 'stomach cancer'/exp OR 'stomach tumor'/exp
  \#2''pepsinogen':ab,ti,kw OR 'pepsinogen I'/exp OR 'pepsinogen II'/exp OR 'pepsinogen I/II':ab,ti,kw OR 'pepsinogen A'/exp OR 'pepsinogen C'/exp
  \#3\#1 AND \#2
  \#4\#3 AND (\[article\]/lim OR \[article in press\]/lim OR \[review\]/lim) AND \[english\]/lim
  **Database: Cochrane Library**
  \#1gastric cancer:ab,ti,kw or gastric neoplasm:ab,ti,kw or stomach cancer:ab,ti,kw or stomach neoplasm:ab,ti,kw or dysplasia:ab,ti,kw
  \#2MeSH descriptor: \[stomach neoplasms\] explode all trees
  \#3\#1 or \#2
  \#4pepsinogen I:ab,ti,kw or pepsinogen II:ab,ti,kw or pepsinogen A:ab,ti,kw or pepsinogen C:ab,ti,kw
  \#5MeSH descriptor: \[pepsinogens\] explode all trees
  \#6\#4 or \#5
  \#7\#3 and \#6
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CAG, chronic atrophic gastritis.

jcm-08-00657-t003_Table 3

###### 

Clinical characteristics of the included studies for the diagnosis of CAG.

  Study                                                 Study Format/Nationality                  Diagnosis                                                                                             Number of Patients   Number of Control   Cut-off Value                            Detection Method of sPGA   Age (Years, Mean ± SD)               Gender (M/F)   Smoking      *H. pylori*                                               TP    FP    FN    TN
  ----------------------------------------------------- ----------------------------------------- ----------------------------------------------------------------------------------------------------- -------------------- ------------------- ---------------------------------------- -------------------------- ------------------------------------ -------------- ------------ --------------------------------------------------------- ----- ----- ----- -----
  Inoue et al. (1998) \[[@B20-jcm-08-00657]\]           Case--control/Japan                       CAG (endoscopic diagnosis without histology)                                                          117                  83                  PG I ≤70 ng/mL and PG I/PG II ratio ≤3   RIA                        Mean 60.5 (range: 34--81)            91/109                                                                                96    21    21    62
  Dinis-Ribeiro et al. (2004) \[[@B21-jcm-08-00657]\]   Cross-sectional /Portugal                 CAG with extensive IM (histopathologic evaluation of all three specimens collected demonstrated IM)   61                   74                  PG I/PG II ratio ≤3                      ELISA                      Median 61 (range: 26--75)            Male: 36.8%                                                                           40    16    21    58
  Nardone et al. (2005) \[[@B22-jcm-08-00657]\]         Case--control/Italy                       CAG (updated Sydney classification)                                                                   30                   64                  PG I/PG II ratio ≤3                      ELISA                      Mean 56 (range: 38--75)              36/58                       44/94 (46.8%)                                             9     0     21    64
  Con et al. (2007) \[[@B23-jcm-08-00657]\]             Case--control/Costa Rica                  CAG (updated Sydney classification)                                                                   58                   165                 PG I ≤70 ng/mL and PG I/PG II ≤3         ELISA                      51.17 ± 12.8                         94/129                      91.4% in patient with CAG, 68.5% in patient without CAG   45    64    13    101
  Iijima et al. (2009) \[[@B24-jcm-08-00657]\]          Case--control/Japan                       CAG                                                                                                   20                   142                 PG I ≤70 ng/mL and PG I/PG II ratio ≤3   ELISA                      Mean 55 (range: 22--79)              95/67                                                                                 15    44    5     98
  Leja et al. (2009) \[[@B25-jcm-08-00657]\]            Case--control/Latvia, Lithuania, Taiwan   CAG (corpus, grade II-III in updated Sydney classification)                                           24                   217                 PG I/PG II ratio \<3                     ELISA                      Mean 66.3 (range: 55--84)            68/173                      165/241 (68.5%)                                           20    28    4     189
  Agkoc et al. (2010) \[[@B26-jcm-08-00657]\]           Case--control/Turkey                      CAG                                                                                                   30                   110                 PG I/PG II ratio \<3                     RIA                        CAG: 60.56 ± 11.29 (range: 36--76)   78/62                                                                                 26    7     4     103
  Yakut et al. (2013) \[[@B27-jcm-08-00657]\]           Case--control/Turkey                      CAG (updated Sydney classification)                                                                   45                   117                 PG I ≤70 ng/mL and PG I/PG II ratio ≤3   ELISA                      55.07 ± 11.91                        75/87          24 (14.8%)   98/162 (60.5%)                                            28    23    17    94
                                                                                                                                                                                                                                                 PG I ≤70 ng/mL                                                                                                                                                                                 28    22    17    95
                                                                                                                                                                                                                                                 PG I/PG II ratio ≤3                                                                                                                                                                            26    12    19    105
  Lee et al. (2014) \[[@B28-jcm-08-00657]\]             Case--control/Korea                       CAG (endoscopic diagnosis without histology)                                                          1216                 1204                PG I/PG II ratio ≤3                      L-TIA                      Mean 57.6                            1506/1052                   1541 (60.2%)                                              775   471   441   733
  Kim et al. (2015) \[[@B29-jcm-08-00657]\]             Cohort/Korea                              CAG (updated Sydney classification) (antrum)                                                          22/95                                    PG I ≤70 ng/mL and PG I/PG II ratio ≤3   L-TIA                      57.7 ± 12.1                          42/53                       12/31 (38.7%) (in CAG) 17/64 (26.6%) (in no CAG)          5     9     17    64
                                                                                                  CAG (corpus)                                                                                          19/95                                                                                                                                                                                                                                   8     6     11    70
  Myint et al. (2015) \[[@B30-jcm-08-00657]\]           Case--control /Myanmar                    CAG (grade I-III in updated Sydney classification)                                                    143                  109                 PG I ≤70 ng/mL and PG I/PG II ratio ≤3   ELISA                      43.6 ± 14.2 (range: 13--85)          97/155                      121/252                                                   11    1     132   108
                                                                                                                                                                                                                                                 PG I/PG II ratio ≤3                                                                                                                                                                            12    1     131   108
  Kotachi et al. (2017) \[[@B31-jcm-08-00657]\]         Case--control/Japan                       CAG (endoscopic diagnosis without histology) (corpus)                                                 370                  170                 PG I ≤70 ng/mL and PG I/PG II ratio ≤3   ELISA                      Mean 61.2                            375/165                     217/540                                                   163   0     207   170
  Leja et al. (2017) \[[@B32-jcm-08-00657]\]            Case--control/Latvia                      CAG (grade II-III in updated Sydney classification)                                                   50                   755                 PG I ≤70 ng/mL and PG I/PG II ratio ≤3   L-TIA                      Median 51 (range: 18--88)            29% male                                                                              38    235   12    520
  Loong et al. (2017) \[[@B33-jcm-08-00657]\]           Cross-sectional /Malaysia                 CAG or IM (updated Sydney classification) (corpus)                                                    37                   35                  PG I ≤70 ng/mL                           ELISA                      56.2 ± 16.2                          33/39                                                                                 3     6     3     60
                                                                                                                                                                                                                                                 PG I/PG II ratio ≤3                                                                                                                                                                            1     2     5     64

sPGA, serum pepsinogen assay; M, male; F, female; SD, standard deviation; TP, true positive; FP, false positive; FN, false negative; TN, true negative; CAG, chronic atrophic gastritis; PG, pepsinogen; RIA, radioimmunoassay; IM, intestinal metaplasia; ELISA, enzyme-linked immunosorbent assay; L-TIA, latex-enhanced turbidimetric immunoassay.
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###### 

Clinical characteristics of the included studies for the diagnosis of GC.

  Study                                                 Study Format/Nationality                                                                     Diagnosis                                                                                                                                              Number of Patients                                                                                                                                     Number of Control                                                                                Cut-off Value                             Detection Method of sPGA   Age (Years, Mean ± SD)                                                                                     Gender (M/F)                                  Smoking                                                            *H. pylori*                                                      TP    FP     FN    TN
  ----------------------------------------------------- -------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------ ----------------------------------------- -------------------------- ---------------------------------------------------------------------------------------------------------- --------------------------------------------- ------------------------------------------------------------------ ---------------------------------------------------------------- ----- ------ ----- --------
  Chang et al. (1992) \[[@B34-jcm-08-00657]\]           Case--control/Taiwan                                                                         GC                                                                                                                                                     192 (175 AGC)                                                                                                                                          70                                                                                               PG I ≤70 ng/mL                            RIA                        GC: 64.6 ± 8.3/control: 51.2 ± 11.2, range: 32--85                                                         235/27                                        112/262 (42.7%)                                                                                                                     124   12     68    58
  Hattori et al. (1995) \[[@B35-jcm-08-00657]\]         Cohort/Japan (follow-up duration: 1 year)                                                    GC (100% adenocarcinoma; 7 undifferentiated- and 11 differentiated-type histology) (sPGA positive subjects were screened by endoscopy)                 18/4876                                                                                                                                                                                                                                                 PG I ≤70 ng/mL and PG I/PG II ratio ≤3    RIA                        Range: 40--61                                                                                              4761/115                                                                                                                                                                          15    1243   3     3615
  Kodoi et al. (1995) \[[@B36-jcm-08-00657]\]           Case--control/Japan                                                                          GC                                                                                                                                                     269 (127 EGCs, 142 AGCs/167 differentiated-, 102 undifferentiated-type histology)                                                                      1345 (sex, age matched)                                                                          PG I\<70 ng/mL and PG I/PG II ratio \<3   RIA                        GC: median 65 (range: 24--80)                                                                              1080/534                                                                                                                                                                          162   543    107   802
  Watanabe et al. (1997) \[[@B37-jcm-08-00657]\]        Nested case--control/Japan                                                                   GC                                                                                                                                                     45                                                                                                                                                     225 (sex-, age-, and address-matched control)                                                    PG I ≤70 ng/mL and PG I/PG II ratio ≤3    RIA                                                                                                                                   156/114                                                                                                          211/270                                                          34    99     11    126
  Kitahara et al. (1999) \[[@B38-jcm-08-00657]\]        Cross-sectional /Japan                                                                       GC                                                                                                                                                     13/5113                                                                                                                                                                                                                                                 PG I ≤70 ng/mL and PG I/PG II ratio ≤3    RIA                        Mean 52.5                                                                                                  2456/2657                                                                                                                                                                         11    1352   2     3748
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    PG I/PG II ratio ≤3                                                                                                                                                                                                                                                                                                                                               11    1673   2     3427
  Dinis-Ribeiro et al. (2004) \[[@B21-jcm-08-00657]\]   Cross-sectional /Portugal                                                                    LGD                                                                                                                                                    23/136                                                                                                                                                                                                                                                  PG I/PG II ratio ≤3                       ELISA                      Median 61 (range: 26--75)                                                                                  50/86                                                                                                                                                                             16    39     7     74
  Ohata et al. (2004) \[[@B39-jcm-08-00657]\]           Cohort/Japan (follow-up duration: mean 7.7 ± 0.9 year)                                       GC (Those with positive double-contrast barium X-ray and/or a positive PG test were further examined by endoscopy)                                     45/4655                                                                                                                                                                                                                                                 PG I/PG II ratio \<3                      RIA                        49.5 ± 4.6                                                                                                 100% male                                                                                                        3657/4655 (78.6%)                                                27    1585   18    3025
  Kim et al. (2005) \[[@B40-jcm-08-00657]\]             Case--control/Korea                                                                          GC                                                                                                                                                     13                                                                                                                                                     30                                                                                               PG I\<70 ng/mL and PG I/PG II ratio \<3   RIA                        Normal endoscopy group: mean 33.4, atrophic gastritis: 47.8, GC: 57                                                                                                                                                                                                                          9     7      4     23
  Watabe et al. (2005) \[[@B41-jcm-08-00657]\]          Cohort/Japan (follow-up duration: mean 4.7 ± 1.7 years)                                      GC                                                                                                                                                     43 (34 intestinal- and 9 diffuse-type histology)/6983                                                                                                                                                                                                   PG I ≤70 ng/mL and PG I/PG II ratio ≤3    RIA                        48.9 ± 8.5                                                                                                 4782/2201                                                                                                        3216/6983 (46.1%) in total, 29/43 (67.4%) in GC                  30    1495   13    5445
  Oishi et al. (2006) \[[@B42-jcm-08-00657]\]           Cohort/Japan (follow-up duration: 14 years)                                                  GC                                                                                                                                                     89/2446                                                                                                                                                                                                                                                 PG I ≤70 ng/mL and PG I/PG II ratio ≤3    RIA                        Mean 57 in male and 59 in female                                                                           1016/1430                                     80.2% in male and 8.2% in female                                   1745/2446 (71.3%) in total and 78/89 (87.6%) in GC               53    661    36    1696
  Sasazuki et al. (2006) \[[@B43-jcm-08-00657]\]        Nested case-control/Japan                                                                    GC (299 differentiated- and 159 undifferentiated-type histology)                                                                                       511                                                                                                                                                    511 (matched for gender, age, study area, blood donation date, fasting time at blood donation)   PG I ≤70 ng/mL and PG I/PG II ratio ≤3    EIA                        57.4 ± 0.32                                                                                                Male: 66.8%                                   GC: 35.7%, control: 30.3%                                                                                                           419   295    92    216
  Sugiu et al. (2006) \[[@B44-jcm-08-00657]\]           Case--control/Japan                                                                          GC                                                                                                                                                     27                                                                                                                                                     65                                                                                               PG I/PG II ratio ≤3                       RIA                        Mean 57.9 (range: 15--88)                                                                                  54/38                                                                                                            100%                                                             23    32     4     33
  Kang et al. (2008) \[[@B45-jcm-08-00657]\]            Case--control/Korea                                                                          GC                                                                                                                                                     380                                                                                                                                                    626                                                                                              PG I ≤70 ng/m                             L-TIA                      57.6 ± 13.2                                                                                                585/421                                                                                                          788/1006 (78.3%)                                                 275   500    105   126
                                                                                                                                                     GC                                                                                                                                                     380                                                                                                                                                    626                                                                                              PG I/PG II ratio ≤3                                                                                                                                                                                                                                                                                                                                               225   244    155   382
                                                                                                                                                     Dysplasia                                                                                                                                              107                                                                                                                                                    899                                                                                              PG I ≤70 ng/m                                                                                                                                                                                                                                                                                                                                                     88    717    19    182
                                                                                                                                                     Dysplasia                                                                                                                                              107                                                                                                                                                    899                                                                                              PG I/PG II ratio ≤3                                                                                                                                                                                                                                                                                                                                               66    351    41    548
  Yanaoka et al. (2008) \[[@B46-jcm-08-00657]\]         Cohort/Japan (follow-up duration: mean 9.7 ± 0.9 years )                                     GC (Those with positive double-contrast barium X-ray and/or a positive PG test were further examined by endoscopy)                                     63/5209                                                                                                                                                                                                                                                 PG I ≤70 ng/mL and PG I/PG II ratio ≤3    RIA                        49.2 ± 4.7                                                                                                 100% male                                                                                                                                                                         37    1370   26    3776
  Yanaoka et al. (2008) \[[@B47-jcm-08-00657]\]         Cohort/Japan (follow-up duration: mean 9.7 ± 0.9 years )                                     GC (Those with positive double-contrast barium X-ray and/or a positive PG test were further examined by endoscopy)                                     63/5209                                                                                                                                                                                                                                                 PG I/PG II ratio ≤3                       RIA                        49.2 ± 4.7                                                                                                 100% male                                                                                                        3656/5209                                                        43    1713   20    3433
  Miki et al. (2009) \[[@B48-jcm-08-00657]\]            Cohort/Japan (follow-up duration: 15 year)                                                   GC including intramucosal cancers (Those with a positive PG test and those with a negative PG test took endoscopy every 2 and 5 years, respectively)   125 (28 EGCs, 72 intramucosal cancers, 25 AGCs)/13789                                                                                                                                                                                                   PG I ≤70 ng/mL and PG I/PG II ratio ≤3    RIA or L-TIA               Mean 48.7                                                                                                  Initial enrollment: 101,892 (85,578/16,314)                                                                                                                                       110   9026   15    4638
  Mizuno et al. (2009) \[[@B49-jcm-08-00657]\]          Cohort/Japan (follow-up duration: 1 year)                                                    GC (PG I level of ≤30 ng/mL and a PG I/PG II ratio of ≤2.0 or those with abnormal X-ray findings were advised to undergo endoscopy)                    19/12120                                                                                                                                                                                                                                                PG I ≤70 ng/mL and PG I/PG II ratio ≤3    CLIA                       Male: median 50 (range: 15--84), Female: median 49 (range: 22--84)                                         7590/4530                                                                                                                                                                         13    1743   6     10,358
  Yamaji et al. (2009) \[[@B50-jcm-08-00657]\]          Cohort/Japan (follow-up duration: mean 4.79 years)                                           GC                                                                                                                                                     37/6158                                                                                                                                                                                                                                                 PG I ≤70 ng/mL and PG I/PG II ratio ≤3    ELISA                      Mean 49                                                                                                    4259/1899                                     2177/6158 (current or past smoker)                                 2901/6158                                                        27    1333   10    4788
  Yanaoka et al. (2009) \[[@B51-jcm-08-00657]\]         Cohort/Japan (follow-up duration: mean 9.3 ± 0.7 years)                                      GC (Those with positive double-contrast barium X-ray and/or a positive PG test were further examined by endoscopy)                                     60 (40 intestinal- and 20 diffuse-type histology)/4129 (3,656 with persistent *H. pylori* infection and 473 with successful *H. pylori* eradication)                                                                                                    PG I ≤70 ng/mL and PG I/PG II ratio ≤3    RIA                        49.8 ± 4.6 in *H. pylori* infection group, 49.6 ± 5.5 in eradication group                                 100% male                                     57.1% in *H. pylori* infection group, 55.4% in eradication group   100% infected                                                    28    1050   32    3019
  Agkoc et al. (2010) \[[@B26-jcm-08-00657]\]           Case--control/Turkey                                                                         GC                                                                                                                                                     50                                                                                                                                                     90                                                                                               PG I/PG II ratio \<3                      RIA                        GC: 65.42 ± 10.28 (range: 38--83)                                                                          78/62                                                                                                                                                                             42    9      8     81
  Kwak et al. (2010) \[[@B52-jcm-08-00657]\]            Cross-sectional/Korea                                                                        GC                                                                                                                                                     460                                                                                                                                                    460                                                                                              PG I/PG II ratio ≤3                       L-TIA                      Mean 57.9                                                                                                  528/392                                                                                                          765 (83.2%)                                                      244   136    216   324
  Mizun et al. (2010) \[[@B53-jcm-08-00657]\]           Cohort/Japan (follow-up duration: median 9.3 years)                                          GC                                                                                                                                                     61/2859                                                                                                                                                                                                                                                 PG I ≤70 ng/mL and PG I/PG II ratio ≤3    RIA                        55--74 category is most prevalent                                                                          1011/1848                                                                                                        2148/2859                                                        44    1079   17    1719
  Aikou et al. (2011) \[[@B54-jcm-08-00657]\]           Case--control/Japan                                                                          GC                                                                                                                                                     183 (107 AGCs, 76 EGCs; 86 differentiated- and 97 undifferentiated-type EGCs)                                                                          269                                                                                              PG I\<70 ng/mL and PG I/PG II ratio \<3   ELISA                      GC: 66.0 ± 10.7/control: 50.1 ± 9.9                                                                        362/90                                                                                                           GC: 62.3%, control: 34.9%                                        82    34     101   235
  Chang et al. (2011) \[[@B55-jcm-08-00657]\]           Case--control/Korea                                                                          Gastric neoplasms                                                                                                                                      297 (61 LGDs, 21 HGDs, 84 EGCs, 131 AGCs)                                                                                                              293                                                                                              PG I/PG II ratio ≤3                       L-TIA                      LGD: 60.2 ± 9.5, HGD: 63.1 ± 8.6, EGC: 59.8 ± 9.2, AGC: 61.6 ± 12.6, control: 50.7 ± 13.6                  368/222                                       Gastric neoplasms: 22.8--51.9%, control: 24.2%                     Gastric neoplasms: 60.7--81%, control: 58%                       184   89     113   204
  Kaise et al. (2011) \[[@B56-jcm-08-00657]\]           Case--control/Japan                                                                          GC                                                                                                                                                     192                                                                                                                                                    1254                                                                                             PG I ≤70 ng/mL and PG I/PG II ratio ≤3    CLIA                       GC: 64.3 ± 9.7/control: 52.3 ± 12.4                                                                        GC: 5:1, control: 1.2:1                       GC: 63%, control: 38.2%                                            GC: 83.9%, control: 30.1%                                        129   229    63    1025
  Kikuchi et al. (2011) \[[@B57-jcm-08-00657]\]         Case--control/Japan                                                                          EGC                                                                                                                                                    122 (114 well- to moderate-differentiated EGCs and 8 poorly-differentiated EGCs)                                                                       178                                                                                              PG I ≤70 ng/mL and PG I/PG II ratio ≤3    CLIA                       GC: 68.2 ± 9.7/control: 56.2 ± 14.9                                                                        187/113                                                                                                          GC: 100/122 (82%), control: 109/178 (61.2%)                      95    68     27    110
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    PG I ≤70 ng/mL                                                                                                                                                                                                                                                                                                                                                    114   148    8     30
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    PG I/PG II ratio ≤3                                                                                                                                                                                                                                                                                                                                               100   83     22    95
  Ito et al. (2012) \[[@B58-jcm-08-00657]\]             Case--control/Japan                                                                          Diffuse-type EGC                                                                                                                                       42                                                                                                                                                     511                                                                                              PG I ≤70 ng/mL and PG I/PG II ratio ≤3    RIA                        GC: mean 57.2 in male, 59.1 in female. Control: mean 58.5                                                  305/248                                                                                                          387/553                                                          20    191    22    320
  Lomba-Viana et al. (2012) \[[@B59-jcm-08-00657]\]     Cohort/Portugal (follow-up duration: 3--5 year)                                              GC                                                                                                                                                     6 (5 intestinal- and 1 diffuse-type histology/3 EGCs and 3 AGCs)/514                                                                                                                                                                                    PG I ≤70 ng/mL and PG I/PG II ratio ≤3    ELISA                      Median 60 (range: 40--79)                                                                                  76/438                                                                                                           165/514 (32.1%)                                                  6     268    3     237
  Zhang et al. (2012) \[[@B60-jcm-08-00657]\]           Cohort/China (follow-up duration: 14 years)                                                  GC                                                                                                                                                     26/1501                                                                                                                                                                                                                                                 PG I ≤70 ng/mL and PG I/PG II ratio ≤3    RIA                        45.29 ± 12.18                                                                                              554/947                                                                                                          995/1501 (66.3%)                                                 9     158    17    1317
  Yakut et al. (2013) \[[@B27-jcm-08-00657]\]           Case--control/Turkey                                                                         Dysplasia                                                                                                                                              37                                                                                                                                                     125                                                                                              PG I ≤70 ng/mL and PG I/PG II ratio ≤3    ELISA                      57.52 ± 11.16                                                                                              75/87                                         24 (14.8%)                                                         98/162 (60.5%)                                                   13    38     24    87
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    PG I ≤70 ng/mL                                                                                                                                                                                                                                                                                                                                                    13    37     24    88
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    PG I/PG II ratio ≤3                                                                                                                                                                                                                                                                                                                                               8     30     29    95
  Choi et al. (2014) \[[@B61-jcm-08-00657]\]            Case--control/Korea                                                                          Gastric neoplasms                                                                                                                                      17                                                                                                                                                     3311                                                                                             PG I ≤70 ng/mL and PG I/PG II ratio ≤3    L-TIA                      Mean 49.8--59.0                                                                                            1979/1349                                                                                                                                                                         9     438    8     2873
  Huang et al. (2014) \[[@B62-jcm-08-00657]\]           Nested case-control/China                                                                    GC                                                                                                                                                     72                                                                                                                                                     37                                                                                               PG I ≤70 ng/mL and PG I/PG II ratio ≤3    CLIA                       GC: 61.7 ± 1.4, control: 56.7 ± 2.8                                                                        GC: 1.23:1. Control: 1.31:1                                                                                      GC: 66.7%, control: 48%                                          27    7      45    30
  Yoshida et al. (2014) \[[@B63-jcm-08-00657]\]         Cohort/Japan (follow-up duration: mean 11.6 ± 4.3 years)                                     GC (those with positive double-contrast barium X-ray and/or a positive PG test were further examined by endoscopy)                                     87/4655                                                                                                                                                                                                                                                 PG I ≤70 ng/mL and PG I/PG II ratio ≤3    RIA                        49.5 ± 4.6                                                                                                 100% male                                     59.3%                                                              3657/4655                                                        48    1314   39    3254
  Zhang et al. (2014) \[[@B64-jcm-08-00657]\]           Case--control/China                                                                          GC                                                                                                                                                     82 (69 AGCs, 13 EGCs)                                                                                                                                  142                                                                                              PG I ≤70 ng/mL                            ELISA                      Patients with gastrointestinal diseases: 52.3 ± 12.3 (range 19--80), control: 52.4 ± 15.1 (range 29--77)   163/85                                        85.4% in patients with GC, 74.4% in control                                                                                         56    25     26    117
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    PG I/PG II ratio ≤3                                                                                                                                                                                                                                                                                                                                               21    2      61    140
  Eybpoosh et al. (2015) \[[@B65-jcm-08-00657]\]        Cross-sectional/Iran                                                                         GC                                                                                                                                                     578 (62 EGCs, 516 AGCs/315 intestinal-, 203 diffuse-, 69 mixed-type histology/274 undifferentiated-, 304 differentiated-type histology)                763                                                                                              PG I ≤70 ng/mL and PG I/PG II ratio ≤3    ELISA                                                                                                                                 750/591                                       399/1341                                                                                                                            100   44     478   719
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    PG I ≤70 ng/mL                                                                                                                                                                                                                                                                                                                                                    133   234    445   529
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    PG I/PG II ratio ≤3                                                                                                                                                                                                                                                                                                                                               32    34     546   729
  Ikeda et al. (2016) \[[@B66-jcm-08-00657]\]           Cohort/Japan (follow-up: at least 20 years)                                                  GC                                                                                                                                                     123/2446                                                                                                                                                                                                                                                PG I ≤70 ng/mL and PG I/PG II ratio ≤3    RIA                        58.3 ± 11.4                                                                                                1016/1430                                     24.6%                                                              1761/2446                                                        70    644    53    1679
  Cho et al. (2017) \[[@B67-jcm-08-00657]\]             Case--control/Korea                                                                          Gastric neoplasms                                                                                                                                      87 (19 LGDs, 16 HGDs, 40 EGCs, 12 AGCs)                                                                                                                311                                                                                              PG I/PG II ratio ≤3                       L-TIA                      48.2 ± 16.6                                                                                                170/228                                                                                                          209/398 (52.5%) (46% with neoplasm vs. 75.9% without neoplasm)   59    62     28    249
  Hamashima et al. (2017) \[[@B68-jcm-08-00657]\]       Nested case-control/Japan                                                                    GC                                                                                                                                                     497                                                                                                                                                    497 (matched for sex, age, blood donation date, and fasting time at blood donation)              PG I/PG II ratio ≤3                       EIA                        57.5 ± 7.2                                                                                                 Male: 66.4%                                                                                                                                                                       432   299    65    198
  Tu et al. (2017) \[[@B69-jcm-08-00657]\]              Cohort/China (follow-up duration: median 11.6 years)                                         GC                                                                                                                                                     86/12018                                                                                                                                                                                                                                                PG I ≤70 ng/mL                            ELISA                      GC: 59.0 ± 10.6/GC-free: 49.6 ± 10.7                                                                       82.6% male in GC/45.1% male in GC-free        39% in GC/36.4% in GC-free                                                                                                          27    3642   59    8290
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    PG I/PG II ratio \<3                                                                                                                                                                                                                                                                                                                                              15    728    71    11204
  Castro et al. (2018) \[[@B70-jcm-08-00657]\]          Cohort/Portugal (follow-up duration: median 6.5 years for sPGA (+)/7.5 years for sPGA (--)   GC (100% adenocarcinoma)                                                                                                                               26/5913                                                                                                                                                                                                                                                 PG I ≤70 ng/mL and PG I/PG II ratio ≤3    ELISA                      Range: 40--74                                                                                              2257/3656                                                                                                                                                                         9     216    17    5671
  Kwak et al. (2018) \[[@B71-jcm-08-00657]\]            Cohort/Korea (follow-up duration: mean 5.6 years)                                            GC                                                                                                                                                     15/3297                                                                                                                                                                                                                                                 PG I ≤70 ng/mL and PG I/PG II ratio ≤3    L-TIA                      51.3 ± 9.4                                                                                                 2326/971                                                                                                         2020/3297                                                        7     567    8     2715
                                                                                                                                                     Gastric neoplasms                                                                                                                                      29/3297                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   12    562    17    2706
  Lee et al. (2018) \[[@B72-jcm-08-00657]\]             Case--control/Korea                                                                          EGC                                                                                                                                                    30                                                                                                                                                     30                                                                                               PG I\<70 ng/mL and PG I/PG II ratio \<3   L-TIA                      59.5 ± 10.7 (patients with EGC) vs. 66.6 ± 12.0 (control)                                                  36/24                                                                                                                                                                             10    2      20    28
  Sjomina et al. (2018) \[[@B73-jcm-08-00657]\]         Cross-sectional/Latvia                                                                       GC                                                                                                                                                     2                                                                                                                                                      257                                                                                              PG I\<70 ng/mL and PG I/PG II ratio \<3   L-TIA                      56.5 ± 12.5                                                                                                82/177                                                                                                           177 (66%)                                                        1     160    1     97
                                                                                                                                                     Gastric dysplasia                                                                                                                                      21                                                                                                                                                     238                                                                                                                                                                                                                                                                                                                                                                                                                                                                17    144    4     94

sPGA, serum pepsinogen assay; M, male; F, female; SD, standard deviation; TP, true positive; FP, false positive; FN, false negative; TN, true negative; GC, gastric cancer; EGC, early gastric cancer; AGC, advanced gastric cancer; LGD, low grade dysplasia; HGD, high grade dysplasia; PG, pepsinogen; RIA, radioimmunoassay; EIA, enzyme immunoassay; CLIA, chemiluminescent immunoassay; ELISA, enzyme-linked immunosorbent assay; L-TIA, latex-enhanced turbidimetric immunoassay.

jcm-08-00657-t005_Table 5

###### 

Summary of DTA and subgroup analysis of the included studies for the diagnosis of CAG.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Subgroup                                                    Number of\   Sensitivity\            Specificity\            PLR                   NLR                     DOR              AUC
                                                              Included\    (95% CI)                (95% CI)                                                                               
                                                              Studies                                                                                                                     
  ----------------------------------------------------------- ------------ ----------------------- ----------------------- --------------------- ----------------------- ---------------- -----------------------
  **Cut-off value: PG I ≤70 ng/mL and PG I/PG II ratio ≤3**   **8**        **0.59 (0.38--0.78)**   **0.89 (0.70--0.97)**   **5.5 (2.3--13.0)**   **0.46 (0.30--0.69)**   **12 (6--25)**   **0.81 (0.77--0.84)**

  Age (years, median or mean)                                                                                                                                                             

  \<60                                                        6            0.54 (0.29--0.78)       0.84 (0.64--0.94)       3.5 (2.1--5.8)        0.54 (0.35--0.84)       6 (4--10)        0.78 (0.74--0.81)

  60≤                                                         2            Null                    Null                    Null                  Null                    Null             Null

  Methodological quality of included studies                                                                                                                                              

  High-quality                                                5            0.68 (0.54--0.79)       0.76 (0.64--0.85)       2.79 (2.04--3.80)     0.43 (0.32--0.57)       7 (4--10)        0.78 (0.74--0.82)

  Low-quality                                                 3            Null                    Null                    Null                  Null                    Null             Null

  **Cut-off value: PG I/PG II ratio ≤3**                      **8**        **0.50 (0.28--0.72)**   **0.94 (0.82--0.98)**   **7.8 (3.3--18.1)**   **0.53 (0.34--0.82)**   **15 (6--37)**   **0.85 (0.81--0.88)**

  Ethnicity                                                                                                                                                                               

  Western                                                     5            0.66 (0.45--0.81)       0.92 (0.81--0.97)       8.5 (3.7--19.4)       0.37 (0.22--0.62)       23 (9--57)       0.88 (0.85--0.91)

  Asian                                                       3            Null                    Null                    Null                  Null                    Null             Null

  Age (years, median or mean)                                                                                                                                                             

  \<60                                                        5            0.31 (0.15--0.53)       0.97 (0.80--0.99)       8.9 (2.2--35.9)       0.71 (0.57--0.89)       12 (3--45)       0.67 (0.62--0.71)

  60≤                                                         3            Null                    Null                    Null                  Null                    Null             Null

  Methodological quality of included studies                                                                                                                                              

  High-quality                                                4            0.66 (0.40--0.85)       0.94 (0.84--0.98)       10.7 (4.8--24.1)      0.36 (0.18--0.71)       30 (11--78)      0.92 (0.90--0.94)

  Low-quality                                                 4            0.32 (0.12--0.62)       0.92 (0.63--0.99)       4.1 (1.4--12.3)       0.73 (0.56--0.97)       6 (2--15)        0.67 (0.63--0.71)

  Total number of included patients                                                                                                                                                       

  \<1000                                                      7            0.49 (0.24--0.74)       0.95 (0.87--0.98)       9.6 (4.8--19.4)       0.54 (0.33--0.89)       18 (8--41)       0.90 (0.87--0.92)

  1000≤                                                       1            Null                    Null                    Null                  Null                    Null             Null
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Subgroups with less than four studies were defined as null because quantitative analysis was not possible. DTA, diagnostic test accuracy; CAG, chronic atrophic gastritis; CI, confidence interval; PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic odds ratio; AUC, area under the curve; PG, pepsinogen. Bold: Summary DTA of the included studies for the diagnosis of CAG.

jcm-08-00657-t006_Table 6

###### 

Summary of DTA and subgroup analysis of the included studies for the diagnosis of GC.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Subgroup                                                    Number of\         Sensitivity\            Specificity\            PLR                  NLR                     DOR            AUC
                                                              Included Studies   (95% CI)                (95% CI)                                                                            
  ----------------------------------------------------------- ------------------ ----------------------- ----------------------- -------------------- ----------------------- -------------- -----------------------
  **Cut-off value: PG I ≤70 ng/mL and PG I/PG II ratio ≤3**   **27**             **0.59 (0.50--0.67)**   **0.73 (0.64--0.81)**   **2.2 (1.7--2.9)**   **0.56 (0.46--0.68)**   **4 (3--6)**   **0.70 (0.66--0.74)**

  Ethnicity                                                                                                                                                                                  

  Asian                                                       24                 0.60 (0.52--0.68)       0.75 (0.68--0.80)       2.4 (2.0--2.8)       0.53 (0.46--0.61)       5 (4--6)       0.73 (0.69--0.77)

  Western                                                     3                  null                    null                    null                 null                    null           null

  Published year                                                                                                                                                                             

  2010--2018                                                  15                 0.46 (0.35--0.57)       0.77 (0.63--0.87)       2.0 (1.2--3.4)       0.70 (0.56--0.89)       3 (1--6)       0.61 (0.57--0.66)

  1995--2009                                                  12                 0.71 (0.64--0.78)       0.68 (0.59--0.76)       2.2 (1.8--2.8)       0.42 (0.34--0.52)       5 (4--8)       0.76 (0.72--0.79)

  Total number of included patients                                                                                                                                                          

  \<1000                                                      9                  0.50 (0.34--0.65)       0.65 (0.44--0.81)       1.4 (0.7--2.8)       0.78 (0.48--1.25)       2 (1--6)       0.58 (0.54--0.62)

  1000≤                                                       18                 0.61 (0.50--0.70)       0.77 (0.68--0.83)       2.6 (2.1--3.2)       0.51 (0.43--0.61)       5 (4--7)       0.74 (0.70--0.78)

  **Cut-off value: PG I ≤70 ng/mL**                           **6**              **0.62 (0.38--0.82)**   **0.57 (0.32--0.79)**   **1.4 (0.9--2.3)**   **0.67 (0.40--1.11)**   **2 (1--5)**   **0.63 (0.58--0.67)**

  Methodological quality of included studies                                                                                                                                                 

  High-quality                                                5                  0.52 (0.33--0.70)       0.66 (0.43--0.83)       1.5 (0.8--2.9)       0.73 (0.47--1.16)       2 (1--6)       0.61 (0.57--0.65)

  Low-quality                                                 1                  null                    null                    null                 null                    null           null

  **Cut-off value: PG I/PG II ratio ≤3**                      **11**             **0.56 (0.35--0.75)**   **0.78 (0.62--0.88)**   **2.5 (1.7--3.7)**   **0.56 (0.39--0.81)**   **4 (3--8)**   **0.74 (0.70--0.78)**

  Ethnicity                                                                                                                                                                                  

  Asian                                                       10                 0.52 (0.30--0.73)       0.75 (0.58--0.87)       2.1 (1.7--2.7)       0.63 (0.47--0.86)       3 (2--5)       0.70 (0.66--0.74)

  Western                                                     1                  null                    null                    null                 null                    null           null
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Subgroups with less than four studies were defined as null because quantitative analysis was not possible. DTA, diagnostic test accuracy; GC, gastric cancer; CI, confidence interval; PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic odds ratio; AUC, area under the curve; PG, pepsinogen. Bold: Summary DTA of the included studies for the diagnosis of GC.
